HCPCS code J1790 – Droperidol injection billing guide
J1790 is the HCPCS Level II code for injection, droperidol, up to 5 mg. It covers droperidol given by intramuscular or slow intravenous injection, mainly to reduce nausea and vomiting around surgical and diagnostic procedures.
One unit equals up to 5 mg, so the usual 2.5 mg adult dose is billed as 1 unit. Droperidol vials are single-dose, so a separately paid Medicare line also needs modifier JZ or JW.
- Level
- Level II
- Category
- J — Drugs administered other than oral method
- Status
- Active
- Billable
- No
- Code also known as
- droperidol injection, Inapsine injection, injectable droperidol, droperidol IM/IV
Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.
- AI-powered code suggestions
- Real-time compliance checks
- Faster claims, fewer denials
Automate repetitive tasks and focus on what matters most—your patients.
Reduce coding errors and ensure compliance with the latest regulations.
Clean claims, fewer denials, and faster reimbursements.
Powerful insights and reporting to help your practice thrive.
HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide
Key takeaways
HCPCS Code J1790 covers injection of droperidol, up to 5 mg, given intramuscularly or by slow intravenous injection.
One billing unit equals up to 5 mg, so the usual 2.5 mg adult dose is billed as 1 unit.
Droperidol vials are single-dose, so a separately paid Medicare line needs modifier JZ, or JW for whole discarded units.
The boxed warning calls for a 12-lead ECG before the dose, so the chart has to show it to support the claim.
Pabau’s claims management software keeps the treatment note, stock record and claim in one patient file, so units and codes match.
HCPCS Code J1790: Definition and code attributes
HCPCS Code J1790 is a Level II HCPCS drug code that describes injection, droperidol, up to 5 mg. The CMS quarterly ASP pricing files list J1790 as droperidol injection, priced per unit of up to 5 mg. CMS maintains HCPCS Level II codes, including J1790, in its annual code set release.
Droperidol is a butyrophenone neuroleptic with sedative and antiemetic effects. It is supplied as a 2.5 mg/mL solution for intramuscular or intravenous use. Some older references wrongly list J1790 as estradiol valerate, which is a different drug billed under J1380.
What J1790 covers and what it excludes
J1790 covers only provider-administered droperidol injections. A few look-alike drugs and products fall outside it.
- Covered: IM or slow IV injection of droperidol in any dose, billed in increments of up to 5 mg per unit.
- Not covered: Droperidol combined with fentanyl citrate (Innovar). That product had its own code, J1810, which CMS has discontinued.
- Not covered: Haloperidol, the other butyrophenone. It is billed under J1630, even though it shares the same 5 mg unit.
- Not covered: Other antiemetics given at the same visit, such as ondansetron or prochlorperazine. Each carries its own J-code on its own line.
- Not covered: Droperidol given during an inpatient stay. The drug is paid inside the inpatient DRG, not billed as J1790 on a Part B claim.
The most common mix-up on a postoperative or emergency claim is J1790 versus J1630. Both drugs are butyrophenones, and both codes use a 5 mg unit. The vial label decides the code, so check it before the line goes out.
Clinical indications and the QT boxed warning
The FDA label for droperidol injection lists one indication. It reduces the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Emergency departments also use it off-label for acute agitation and migraine headache, where payer rules on off-label use apply.
The label carries a boxed warning for QT prolongation and torsade de pointes, reported at or below recommended doses. That warning shapes the claim as much as the care, because it sets what the chart has to show.
- ECG before the dose: every patient needs a 12-lead ECG first. Droperidol should not be given when the QTc exceeds 440 msec in males or 450 msec in females.
- Monitoring after the dose: when the benefit is judged to outweigh the risk, ECG monitoring continues for 2 to 3 hours after treatment.
- Second-line use: the label reserves droperidol for patients who fail to respond to other adequate treatments.
- Contraindication: known or suspected QT prolongation, including congenital long QT syndrome.
- Dosing: the maximum recommended initial adult dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses may follow with caution.
ICD-10 diagnosis codes for J1790
Medical necessity for J1790 rests on the diagnosis code on the claim line. R11.2 is the most common pairing, used for postoperative nausea with vomiting. The table below maps it and the other common scenarios to their ICD-10-CM codes.
When droperidol is given to prevent nausea, before any symptom appears, the claim carries the diagnosis for the procedure itself. Check the applicable MAC’s policy, since some contractors expect a symptom code on the drug line.
How to bill J1790: Units, NDC, modifiers and the administration code
A clean J1790 line needs four things. Those are the right unit count, a valid NDC, the correct wastage modifier and a matching administration code. Claims management software that checks each element before submission cuts manual entry errors. A clean claim is always faster than working a denial.
Unit calculation
One billing unit of J1790 equals up to 5 mg of droperidol. Divide the administered dose by 5 and round up to the nearest whole unit.
NDC reporting
Medicaid and many commercial payers require the NDC on the drug line, and Medicare asks for it on dual-eligible crossover claims. Report it in 11-digit 5-4-2 format with qualifier N4, then the quantity and unit of measure, usually ML.
CMS’s October 2026 ASP crosswalk lists two Hikma packages for J1790. These are 00143-9515-25 (1 mL vials) and 00143-9514-25 (2 mL vials). American Regent also markets 2 mL vials under NDC 0517-9702-25. Always copy the NDC from the vial you used.
JW and JZ modifiers
The droperidol vials CMS crosswalks to J1790 are all single-dose, so the CMS wastage rules apply to any separately paid Part B line. Medicare has required JZ since July 1, 2023 when no drug is discarded from a single-dose container.
J1790 does not appear on CMS’s JW and JZ code list, which leads some billers to drop the modifier. CMS says that list is not all-inclusive, and single-dose container drugs still need JW or JZ when they are not on it.
The common case looks like waste but is not billed as waste. A 2.5 mg dose drawn from a 5 mg vial leaves 2.5 mg in the vial. The CMS JW and JZ FAQ says JW is not used when the dose is less than the billing unit. Bill 1 unit with JZ instead.
- 2.5 mg from a 1 mL vial: the vial is empty, so bill 1 unit with JZ.
- 2.5 mg from a 2 mL vial: the leftover 2.5 mg sits inside the billed unit. Bill 1 unit with JZ and no JW line.
- Two vials opened, 3.75 mg given: 10 mg was opened and 1 unit was billed. The second whole unit of waste goes on a separate JW line.
- Packaged drug lines: JW and JZ do not apply when the drug is packaged under OPPS (status indicator N), or in an RHC or FQHC.
Put together, the dose decides the unit count and the vial decides the modifier, as the chart below shows.

Pro Tip
Set the default J1790 line in your billing system to 1 unit with JZ. That matches the usual 2.5 mg dose from either vial size. Change it only when the dose passes 5 mg or a second vial leaves a whole unit of waste.
Administration code
The administration code depends on the route. CPT 96372 covers a therapeutic, prophylactic or diagnostic injection given IM or subcutaneously. CPT 96374 covers a single or initial IV push of a drug.
When droperidol follows another drug by IV push at the same encounter, CPT 96375 reports each sequential push of a new substance. When an anesthesia provider gives the dose during a case, the administration is part of the anesthesia service. Only the drug is reported then, usually on the facility claim.
Medicare and commercial payer rates for J1790
Medicare Part B pays J1790 under the Average Sales Price (ASP) methodology, at ASP plus 6% in the physician office. The October to December 2026 payment limit is $5.348 per unit of up to 5 mg, with 20% patient coinsurance. ASP rates reset every quarter, so check the current file before quoting an expected payment.
In the hospital outpatient department, a drug this inexpensive is usually packaged into the payment for the main procedure. Check the current OPPS Addendum B for the J1790 status indicator. Commercial allowables are contract-specific and often tied to a percentage of ASP or average wholesale price.
Codes confused with HCPCS Code J1790
Four codes account for most J1790 substitution errors. The table below shows what each one bills and when it applies.
Documentation requirements for J1790 claims
Complete documentation for J1790 covers the clinical record and the claim line together. The boxed warning adds cardiac items that most J-code charts never need. A superbill that captures each field at the point of care keeps omissions off the claim.
- Prescriber order: drug name, dose in mg, route (IM or IV), timing and prescriber signature.
- Baseline ECG: a 12-lead ECG before the dose, with the QTc recorded.
- Post-dose monitoring: ECG monitoring for 2 to 3 hours where the label calls for it, with any arrhythmia noted.
- Indication: the diagnosis, and why droperidol was chosen over other antiemetics, since the label makes it second-line.
- Drug details: dose given, NDC, lot number, expiration date and amount discarded from the vial.
- Administration: route, site, time and the administering clinician’s name and credentials.
- Response: the effect on symptoms and any adverse reaction, such as sedation, hypotension or restlessness.
Common J1790 claim denial reasons and how to fix them
Most J1790 denials are preventable. Denial management workflows for J-code claims follow one pattern. Identify the CARC reason code, correct the source error, then resubmit or appeal with documentation.
How Pabau keeps J1790 claims consistent from injection to payment
A J1790 line touches three records. The dose and ECG sit in the treatment note, the NDC and lot sit on the vial, and the diagnosis sits in the chart. When a biller copies each one into a separate claims tool, small mismatches creep in.
Pabau, the practice management platform we build, keeps those pieces in one patient record. The treatment note, the vial logged in stock, the invoice and the claim sit together. Units, modifier and diagnosis are checked against the same visit.

The result is fewer resubmissions on a low-value drug line that is rarely worth an appeal. Your team works errors from one dashboard, and the days-overdue column shows which payer is holding money longest.
Submit clean J1790 claims the first time
Pabau keeps the treatment note, stock record and claim in one patient file, so J1790 units, NDC, modifier and diagnosis match before submission.

Conclusion
J1790 is a cheap drug line with an expensive failure mode. The unit math is easy, since one 5 mg unit covers almost every dose. The modifier is where claims slip, because a 2.5 mg dose from a 5 mg vial still takes JZ rather than a JW line.
The chart carries the other half of the risk. A baseline ECG and a reason for choosing a second-line antiemetic are what an auditor looks for first. Build both into the order set, and the claim follows from the note.
Book a demo to see how Pabau keeps dose, NDC and diagnosis in one record so your J1790 claims go out clean.
Continue your research
Billing ondansetron at the same visit? HCPCS code J2405 covers ondansetron units per 1 mg and how they differ from J1790.
Need to understand denial codes on your remittance? Denial codes in medical billing explains CARC and RARC codes and how to respond to each.
Want a primer on the revenue cycle for injectable drug claims? What is revenue cycle management covers the claim workflow from eligibility through payment posting.
Frequently asked questions
What does HCPCS code J1790 cover?
HCPCS Code J1790 covers injection of droperidol, billed in units of up to 5 mg each. It applies to droperidol given IM or by slow IV injection by a provider. Haloperidol (J1630), ondansetron (J2405) and the discontinued droperidol and fentanyl product (J1810) fall outside this code.
How many units do I bill for J1790?
Bill one unit of J1790 for each 5 mg, or fraction of 5 mg, of droperidol administered. The usual 2.5 mg adult dose is 1 unit, and so is a 3.75 mg total. A dose above 5 mg is 2 units.
Do I use the JW or JZ modifier with J1790?
Usually JZ, on separately paid Part B lines, because droperidol vials are single-dose containers. A 2.5 mg dose from a 5 mg vial is billed as 1 unit with JZ. CMS does not allow JW when the dose is less than the billing unit.
Which administration code is billed with J1790?
CPT 96372 covers an IM injection, and CPT 96374 covers a single or initial IV push. CPT 96375 applies when droperidol is a sequential IV push after another drug. During anesthesia, the administration is part of the anesthesia service.
What ICD-10 codes support J1790?
R11.2 (nausea with vomiting, unspecified) is the most common pairing. R11.0 and R11.10 cover nausea or vomiting alone. Off-label uses are coded to the documented condition, such as R45.1 for agitation or a G43 migraine code.
Why does a J1790 claim need ECG documentation?
Droperidol carries a boxed warning for QT prolongation and torsade de pointes. The label calls for a 12-lead ECG before administration, and monitoring for 2 to 3 hours afterward. A chart without the ECG weakens the claim on audit.



